 | Up a level |
Perk, J; De Backer, G; Gohlke, H; Graham, I; Reiner, Z; Verschuren, M; Albus, c; Benlian, P; Boysen, G; Cifkova, R; Deaton, C; Ebrahim, S; Fisher, M; Germano, G; Hobbs, R; Hoes, A; Karadeniz, S; Mezzani, A; Prescott, E; Ryden, L; ... (2012). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Heart Journal, 33(13), pp. 1635-1701. Oxford: Oxford University Press 10.1093/eurheartj/ehs092
Bousser, M G; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M; Mattle, H P; Rothwell, P M (2009). The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. Cerebrovascular diseases, 27(6), pp. 608-13. Basel: Karger 10.1159/000216835
Bousser, M G; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, K; Hennerici, M G; Mattle, H P; Rothwell, P M (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular diseases, 27(5), pp. 509-18. Basel: Karger 10.1159/000212671
